Vasculoprotective Effects of Vildagliptin. Focus on Atherogenesis

Vildagliptin is a representative of Dipeptidyl Peptidase-4 (DPP-4) inhibitors, antihyperglycemic drugs, approved for use as monotherapy and combination therapy in type 2 diabetes mellitus. By inhibiting enzymatic decomposition, DPP-4 inhibitors increase the half-life of incretins such as GLP-1 (Gluc...

Descrición completa

Gardado en:
Detalles Bibliográficos
Main Authors: Michał Wiciński, Karol Górski, Eryk Wódkiewicz, Maciej Walczak, Magdalena Nowaczewska, Bartosz Malinowski
Formato: Artigo
Idioma:Inglês
Publicado: MDPI AG 2020-03-01
Series:International Journal of Molecular Sciences
Assuntos:
vildagliptin
endothelium
inflammation
atherogenesis
pathways
pharmacology
Acceso en liña:https://www.mdpi.com/1422-0067/21/7/2275
Tags: Engadir etiqueta
Sen Etiquetas, Sexa o primeiro en etiquetar este rexistro!

Títulos similares